A citation-based method for searching scientific literature

Fränce Hardtstock, David Myers, Tracy Li, Diana Cizova, Ulf Maywald, Thomas Wilke, Frank Griesinger. BMC Cancer 2020
Times Cited: 4







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.
William D Travis, Elisabeth Brambilla, Gregory J Riely. J Clin Oncol 2013
306
25

Assessment of lung cancer risk factors by histologic category.
J H Lubin, W J Blot. J Natl Cancer Inst 1984
226
25

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. J Clin Oncol 2019
520
25

Impact of filter cigarette smoking on lung cancer histology.
S D Stellman, J E Muscat, D Hoffmann, E L Wynder. Prev Med 1997
45
25

Targeted Therapy and Immunotherapy for Lung Cancer.
Evan C Naylor, Jatin K Desani, Paul K Chung. Surg Oncol Clin N Am 2016
46
25

Screening for epidermal growth factor receptor mutations in lung cancer.
Rafael Rosell, Teresa Moran, Cristina Queralt, Rut Porta, Felipe Cardenal, Carlos Camps, Margarita Majem, Guillermo Lopez-Vivanco, Dolores Isla, Mariano Provencio,[...]. N Engl J Med 2009
25


Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.
K M Kerr, L Bubendorf, M J Edelman, A Marchetti, T Mok, S Novello, K O'Byrne, R Stahel, S Peters, E Felip. Ann Oncol 2014
164
25

Patterns of lung cancer risk according to type of cigarette smoked.
J H Lubin, W J Blot, F Berrino, R Flamant, C R Gillis, M Kunze, D Schmahl, G Visco. Int J Cancer 1984
132
25

Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer.
Manish K Thakur, Shirish M Gadgeel. Semin Respir Crit Care Med 2016
29
25

Lung Cancer in Georgia.
Ivane Kiladze, Elene Mariamidze, Branislav Jeremic. J Thorac Oncol 2020
2
50


Biomarker Testing for Personalized Therapy in Lung Cancer in Low- and Middle-Income Countries.
Fred R Hirsch, Bojan Zaric, Ahmed Rabea, Sumitra Thongprasert, Nirush Lertprasertsuke, Mercedes Liliana Dalurzo, Marileila Varella-Garcia. Am Soc Clin Oncol Educ Book 2017
4
25

Lung cancer in developing countries: access to molecular testing.
Carlos Gil Ferreira. Am Soc Clin Oncol Educ Book 2013
9
25

What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements.
Wendy A Cooper, Sandra O'toole, Michael Boyer, Lisa Horvath, Annabelle Mahar. Pathology 2011
49
25

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.
A D'Incecco, M Andreozzi, V Ludovini, E Rossi, A Capodanno, L Landi, C Tibaldi, G Minuti, J Salvini, E Coppi,[...]. Br J Cancer 2015
391
25

Molecular profiling in non-small cell lung cancer: a step toward personalized medicine.
Kirtee Raparia, Celina Villa, Malcolm M DeCamp, Jyoti D Patel, Minesh P Mehta. Arch Pathol Lab Med 2013
29
25

ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.
Francesca Casaluce, Assunta Sgambato, Paolo Maione, Antonio Rossi, Carmine Ferrara, Alba Napolitano, Giovanni Palazzolo, Fortunato Ciardiello, Cesare Gridelli. Target Oncol 2013
58
25

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Mark G Kris, Bruce E Johnson, Lynne D Berry, David J Kwiatkowski, A John Iafrate, Ignacio I Wistuba, Marileila Varella-Garcia, Wilbur A Franklin, Samuel L Aronson, Pei-Fang Su,[...]. JAMA 2014
981
25



Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
Neal I Lindeman, Philip T Cagle, Mary Beth Beasley, Dhananjay Arun Chitale, Sanja Dacic, Giuseppe Giaccone, Robert Brian Jenkins, David J Kwiatkowski, Juan-Sebastian Saldivar, Jeremy Squire,[...]. Arch Pathol Lab Med 2013
317
25

Targeted therapies and immunotherapy in non-small-cell lung cancer.
D Cortinovis, M Abbate, P Bidoli, S Capici, S Canova. Ecancermedicalscience 2016
20
25

Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Deepa Rangachari, Paul A VanderLaan, Meghan Shea, Xiuning Le, Mark S Huberman, Susumu S Kobayashi, Daniel B Costa. J Thorac Oncol 2017
89
25

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.
K Azuma, K Ota, A Kawahara, S Hattori, E Iwama, T Harada, K Matsumoto, K Takayama, S Takamori, M Kage,[...]. Ann Oncol 2014
425
25

Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.
Gaurav Singal, Peter G Miller, Vineeta Agarwala, Gerald Li, Gaurav Kaushik, Daniel Backenroth, Anala Gossai, Garrett M Frampton, Aracelis Z Torres, Erik M Lehnert,[...]. JAMA 2019
151
25


Female lung cancer.
V L Ernster. Annu Rev Public Health 1996
54
25

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
David M Jackman, Vincent A Miller, Leigh-Anne Cioffredi, Beow Y Yeap, Pasi A Jänne, Gregory J Riely, Marielle Gallegos Ruiz, Giuseppe Giaccone, Lecia V Sequist, Bruce E Johnson. Clin Cancer Res 2009
312
25


Lung cancer in Europe in 2000: epidemiology, prevention, and early detection.
Jerzy E Tyczynski, Freddie Bray, D Maxwell Parkin. Lancet Oncol 2003
153
25

Effect of tobacco smoking on various histological types of lung cancer.
W Jedrychowski, H Becher, J Wahrendorf, Z Basa-Cierpialek, K Gomola. J Cancer Res Clin Oncol 1992
42
25

Global cancer statistics, 2002.
D Max Parkin, Freddie Bray, J Ferlay, Paola Pisani. CA Cancer J Clin 2005
25

International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women.
J Lortet-Tieulent, I Soerjomataram, J Ferlay, M Rutherford, E Weiderpass, F Bray. Lung Cancer 2014
192
25


The epidemiology of lung cancer.
S Franceschi, E Bidoli. Ann Oncol 1999
49
25


Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?
Adi F Gazdar, Hisayuki Shigematsu, Joachim Herz, John D Minna. Trends Mol Med 2004
238
25

First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment.
Vamsidhar Velcheti, Sheenu Chandwani, Xin Chen, M Catherine Pietanza, Thomas Burke. Immunotherapy 2019
16
25


Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007.
Sarah Walters, Camille Maringe, Michel P Coleman, Michael D Peake, John Butler, Nicholas Young, Stefan Bergström, Louise Hanna, Erik Jakobsen, Karl Kölbeck,[...]. Thorax 2013
292
25

Immuno-oncology-the new paradigm of lung cancer treatment.
D E Dawe, C H Harlos, R A Juergens. Curr Oncol 2020
3
33

Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
Jean Bernard Auliac, Maurice Pérol, David Planchard, Isabelle Monnet, Marie Wislez, Hélène Doubre, Florian Guisier, Eric Pichon, Laurent Greillier, Bénédicte Mastroianni,[...]. Lung Cancer 2019
25
25

Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices.
Vamsidhar Velcheti, Sheenu Chandwani, Xin Chen, M Catherine Pietanza, Bilal Piperdi, Thomas Burke. Immunotherapy 2019
15
25

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
25


Global cancer statistics.
Ahmedin Jemal, Freddie Bray, Melissa M Center, Jacques Ferlay, Elizabeth Ward, David Forman. CA Cancer J Clin 2011
25

Immune checkpoint blockade for non-small cell lung cancer: What is the role in the special populations?
R Califano, F Gomes, C J Ackermann, S Rafee, G Tsakonas, S Ekman. Eur J Cancer 2020
19
25

Median regression with censored cost data.
Heejung Bang, Anastasios A Tsiatis. Biometrics 2002
69
25

Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
Doran Ksienski, Elaine S Wai, Nicole Croteau, Ashley T Freeman, Angela Chan, Leathia Fiorino, Edward G Brooks, Zia Poonja, David Fenton, Georgia Geller,[...]. Lung Cancer 2019
22
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.